Skip to content
Screener

Net Change in Cash at other companies

Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Amgen logo
AmgenAMGN
$1.95B+349%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$198.88M-999%
Arrowhead Research logo
Arrowhead ResearchARWR
-$14.12M-111%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$49.73M+379%
Regenxbio logo
RegenxbioRGNX
$21.26M

Other financials

Income statement

See full
Revenue$214.0M+28.1%
Operating income-$75.0M+30.6%
Net income-$92.0M+20.0%
EPS (diluted)-$0.90+23.1%

Balance sheet

See full
Cash & equivalents$125.0M-29.0%
Total debt$36.0M-10.8%
Total equity-$291.0M-293%
Total assets$1.3B-3.2%

Cash flow

See full
Operating cash flow-$97.0M+11.0%
CapEx$1.0M-66.7%
Free cash flow-$98.0M+12.5%

Valuation

See full
Market cap$2.55B-5.8%
P/S3.6×-0.9×

Profitability

See full
Gross margin97.2%
Operating margin-73.6%-7.3pp
Net margin-81.7%-4.9pp
FCF margin-68.2%-1.7pp

Returns & leverage

See full
Return on equity-325.6%+36.9pp
Debt / equity3.7×
Current ratio1.7×-0.7×

Where this comes from

Reported directly by Ultragenyx Pharmaceutical in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The source filing: Ultragenyx Pharmaceutical’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333233
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Financing activities:
Proceeds from the issuance of common stock in connection with at-the-market offering, net80
Proceeds from the issuance of common stock under equity plans, net34
Net cash provided by financing activities384
Effect of exchange rate changes on cash5
Net (decrease) increase in cash, cash equivalents and restricted cash(296)5
Cash, cash equivalents and restricted cash at beginning of period436184
Cash, cash equivalents and restricted cash at end of period$140$189

Item 1. Financial Statements

FAQ

What is Ultragenyx Pharmaceutical's net change in cash?
Ultragenyx Pharmaceutical (RARE) reported net change in cash of -$49M in Q2 2026.
How has Ultragenyx Pharmaceutical's net change in cash changed year-over-year?
Ultragenyx Pharmaceutical's net change in cash decreased by 198.0% year-over-year, from $50M to -$49M.
What is the long-term trend for Ultragenyx Pharmaceutical's net change in cash?
Over 2 years (2022 to 2025), Ultragenyx Pharmaceutical's net change in cash has grown at a 18.8% compound annual growth rate (CAGR), from -$178.49M to $252M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Ultragenyx Pharmaceutical's net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude